Immunoreactivity of p53, Mdm2, p21WAF1/CIP1, Bcl-2, and bax in soft tissue sarcomas: Correlation with histologic grade

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 1, 2007, Pages 64-69

  Sabah, Muna ^a   Cummins, Robert ^a   Leader, Mary ^a   Kay, Elaine ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Apoptosis; p53 pathway; Soft tissue sarcoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CORRELATION ANALYSIS; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

BCL-2-ASSOCIATED X PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247642826     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000201809.43554.ed     Document Type: Article

References (37)

1. Cordon-Cardo C. Molecular biology of sarcomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia: JB Lippincott Company; 1997:1731-1738.
2. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
3. Clurman BE, Roberts JM. Cell cycle and cancer. J Natl Cancer Inst. 1995;87:1499-1501.
4. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer. 1994;73:2499-2505.
5. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995;147:545-560.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
7. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans. 2001;29:684-688.
8. Fletcher CD, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. Oxford: Oxford University Press; 2002.
9. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350-362.
10. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. USA: Mosby; 2001.
11. Antonescu CR, Leung DH, Dudas M, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977-983.
12. Yoo J, Park SY, Kang SJ, et al. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002;126:567-573.
13. Stefanou DG, Nonni AV, Agnantis NJ, et al. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study. Anticancer Res. 1998;18:4673-4681.
14. Soini Y, Vahakangas K, Nuorva K, et al. p53 immunohistochemistry in malignant fibrous histiocytoma and other mesenchymal tumours. J Pathol. 1992;168:29-33.
15. Rieske P, Bartkowiak JK, Szadowska AM, et al. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. J Exp Clin Cancer Res. 1999;18:403-416.
16. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54:794-799.
17. Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 1996;56:4134-4136.
18. Wurl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998;16:1183-1185.
19. Szadowska A, Olborski B, Harezga-Bal B, et al. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas. Pol J Pathol. 1999;50:9-16.
20. Hillemanns M, Pasold S, Bottcher K, et al. Prognostic factors of gastrointestinal stromal tumors of the stomach. Verh Dtsch Ges Pathol. 1998;82:261-266.
21. Schneider-Stock R, Ziegeler A, Haeckel C, et al. Prognostic relevance of p53 alterations and mib-1 proliferation index in subgroups of primary liposarcomas. Clin Cancer Res. 1999;5:2830-2835.
22. Nakanishi H, Ohsawa M, Naka N, et al. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology. 1997;54:238-244.
23. Chen J, Wu X, Lin J, et al. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996;16:2445-2452.
24. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83.
25. Nakayama T, Toguchida J, Wadayama B, et al. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer. 1995; 64:342-346.
26. Nilbert M, Rydholm A, Willen H, et al. MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. Genes Chromosome Cancer. 1994;9:261-265.
27. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53:2231-2234.
28. Florenes VA, Maelandsmo GM, Forus A, et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 1994;86:1297-1302.
29. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701-704.
30. El Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-1174.
31. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391-3395.
32. Dei Tos AP, Piccinin S, Doglioni C, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151:1531-1539.
33. Adachi T, Oda Y, Sakamoto A, et al. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int J Surg Pathol. 2001;9:99-109.
34. Kawauchi S, Fukuda T, Oda Y, et al. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins. Mod Pathol. 2000;13:755-765.
35. Hirakawa N, Naka T, Yamamoto I, et al. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol. 1996;27:1060-1065.
36. Lopes JM, Nesland JM, Reis-Filho JS, et al. Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin. Histopathology. 2002;40:464-471.
37. Dan'ura T, Kawai A, Morimoto Y, et al. Apoptosis and expression of its regulatory proteins in soft tissue sarcomas. Cancer Lett. 2002;178:167-174.